Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 404 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06670911RecruitingPhase 2
Lower dose pembrolizumab with chemo for advanced cervical cancer
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07544784RecruitingPhase 2
AK104 plus radiation for colorectal cancer spread to liver
This study tests a new immunotherapy drug called AK104 combined with radiation therapy and standard chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if adding AK104 and targeted radiation improves treatment outcomes compared to standard therapy alone.
ShanghaiAges 18 years+ - NCT06429696RecruitingPhase 2
Maintenance therapy for extensive stage small cell lung cancer
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06430437RecruitingPhase 3
Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06466434RecruitingPhase 2
Prebiotic diet to boost immunotherapy for melanoma
This trial tests whether a special prebiotic diet can help your body's bacteria (microbiome) better respond to standard immunotherapy for advanced melanoma that cannot be removed by surgery. If you are starting your first immunotherapy, you may be able to join.
Houston, TexasAges 18 years+ - NCT07190677Recruiting
Nivolumab plus ipilimumab with chemo for advanced lung cancer
This trial tests combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy as a first treatment for advanced lung cancer that has spread or come back. It may help if your cancer hasn't been treated before and doesn't have certain genetic changes.
Pavia, LombardyAges Any age - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07487896RecruitingPhase 3
YL201 vs. chemo for advanced esophageal cancer after first treatment
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Anqing, AnhuiAges 18 years+ - NCT07439445Recruiting
Simplified treatment for H. pylori guided by a stool test
This trial tests a simpler two-drug treatment for H. pylori infection, chosen based on a stool test that checks if the bacteria are resistant to clarithromycin. It may help people who have not been treated before avoid unnecessary antibiotics.
Beijing, Beijing MunicipalityAges 18–70 - NCT06892054RecruitingPhase 1
Targeted therapy plus chemo for advanced pancreatic cancer
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Avignon, FranceAges 18 years+ - NCT07425795RecruitingPhase 2
Tislelizumab with chemo and radiation for first-line extensive SCLC
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07413042RecruitingPhase 1
Radiation drug combined with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
Beijing, Beijing MunicipalityAges 18–80 - NCT07122024RecruitingPhase 4
Testing a dual therapy for H. pylori treatment
This trial tests a two-drug treatment (keverprazan and amoxicillin) for people who have H. pylori and have not been treated for it before. The goal is to see if this newer combination works well and is safe.
Hangzhou, ZhejiangAges 18–65 - NCT07391618RecruitingPhase 2
First treatment for advanced colorectal cancer with combo chemo
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
BeijingAges 18–75 - NCT06362252RecruitingPhase 1/Phase 2
I-DXd plus atezolizumab for first-line extensive SCLC
This trial tests a new combination of drugs (I-DXd and atezolizumab, with or without carboplatin) as your first treatment for extensive stage small cell lung cancer. It has two groups: one for people who haven't started treatment yet, and another for those who've already had 4 cycles of a standard chemo-immunotherapy combination and are stable or better.
Birmingham, AlabamaAges 18 years+ - NCT07340723RecruitingPhase 2
New treatment study for grade II acute GVHD after transplant
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07306286RecruitingPhase 2
Cryoablation plus immunotherapy for advanced pancreatic cancer
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07171606RecruitingPhase 2
Study of a new drug for advanced lung cancer
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
ShanghaiAges 18–75 - NCT07478302RecruitingPhase 1
A study of two drugs for untreated advanced liver cancer
This trial tests a combination of two medications, SHR-2524 and bevacizumab, as a first treatment for people with advanced hepatocellular carcinoma (a type of liver cancer) that has not been treated with cancer drugs before. The goal is to see if this combination can help shrink or control the cancer.
Fuzhou, FujianAges 18 years+ - NCT06486883RecruitingPhase 2
T-DXd vs CDK4/6i plus hormone therapy for advanced HR-positive, HER2-low breast cancer
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
GrazAges 18 years+ - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 404 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.